Phase 3 efficacy/safety study of midazolam nasal spray for seizures in the epilepsy monitoring unit

Takeaway

  • Midazolam nasal spray (MDZ-NS) maintained efficacy for ≥6 hours post-dose, was well-tolerated, and although the treatment difference was not statistically different from placebo, may offer clinically meaningful improvement to people in the epilepsy monitoring unit (EMU).

Why this matters

    MDZ-NS is approved for the acute treatment of stereotypic, intermittent episodes of seizure activity, however, people admitted to the EMU experience seizure clusters that may be different from naturally-occurring seizures and the efficacy and safety of MDZ-NS in this population has not yet been confirmed.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.